Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Consensus estimates compiled by EvaluatePharma reflect this with forecast sales of Vumerity at a modest $111m in 2024.
Some analysts think it is likely to be an also-ran in the market, with EvaluatePharma predicting around $110 million in sales in 2024, although others are more…
"Technologies such as Crispr are highly valued," says a study by the British analysis company EvaluatePharma, "but they also represent a high risk. Any serious setback…
The sell-side expects tucatinib to post 2024 sales of $268 million, according to EvaluatePharma consensus.
According to estimates by market research firm Evaluate Pharma, the annual increase in prescription drug sales between 2019 and 2024 will reach almost 7% worldwide.
EvaluatePharma consensus predicts 2024 palovarotene sales of $357m; there are currently no forecasts for BLU-782, presumably because of its early stage.
According to an estimate by data service provider EvaluatePharma, about $ 182 billion will be spent on research and development this year, much of it to fight more than…
The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…
This latest approval will allow Keytruda to continue on its upwards trajectory – Evaluate Pharma has forecasted that it will be the top-selling drug worldwide in 2024 at…
Analysts think that Beovu has the potential to grow quickly to blockbuster sales levels, with...EvaluatePharma pegging it at a more modest $1.3bn in 2024.